All In Biotech

Drug Trial Radar · NCT00794885

China Stroke Primary Prevention Trial

Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.

Last checked: Nov 19, 2026Latest source record: Aug 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 20,702 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20,702

Actual

Start

May 2008

Primary completion

Aug 2013

Study completion Jun 2014

Sponsor

Lead sponsor
Shenzhen Ausa Pharmed Co.,LtdIndustry
Sponsor type
Industry
Collaborators
Anhui Medical University
First posted
Nov 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.

Conditions

  • Primary Hypertension

Interventions

  • Enalapril/folic acidDrug

    Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.

  • Enalapril maleateDrug

    Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First attack of symptomatic stroke ( ischemic or hemorrhagic)Time frame: during the trial period

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Anqing Branch, Anhui Institute of Biomedical Research

    Anqing, Anhui, China

  • Lianyungang Center for Advanced Research in Cardiovascular Diseases

    Lianyungang, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.